WaveMan
WaveMan · Company
CPIX · Cumberland Pharmaceuticals Inc
> Search tickers & screens ⌘K
LIVE
← All companies

CPIX Cumberland Pharmaceuticals (CPIX) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001087294
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
17
13F, latest reported quarter

Cumberland Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for CUMBERLAND PHARMACEUTICALS INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Young Caroline
Director
BUY
2025-09-12 SECtraded 2025-08-29
6
$21
+223.9%
Context
  • 526 earlier Form 4 trades (code P or S) here by this insider (526 buys), the last on Aug 28, 2025.
  • -29.6% median (-21.9% mean) 90-day return after 30 previous buys.
  • The trade is 0.0% of the 32,942 shares held after it.
  • 3 other insiders bought within 30 days.
  • 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Young Caroline bought about $21 of CPIX on Aug 29, 2025; 3 other insiders bought within 30 days and 17 funds added in the latest 13F quarter.
Jones James
Director
BUY
2025-09-12 SECtraded 2025-08-29
13
$45
+223.9%
Context
  • 470 earlier Form 4 trades (code P or S) here by this insider (470 buys), the last on Aug 28, 2025.
  • -29.6% median (-21.9% mean) 90-day return after 30 previous buys.
  • The trade is 0.0% of the 43,938 shares held after it.
  • 3 other insiders bought within 30 days.
  • 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Jones James bought about $45 of CPIX on Aug 29, 2025; 3 other insiders bought within 30 days and 17 funds added in the latest 13F quarter.
KAZIMI A J
Chairman and CEO
BUY
2025-09-12 SECtraded 2025-08-29
13
$45
+223.9%
Context
  • 355 earlier Form 4 trades (code P or S) here by this insider (355 buys), the last on Aug 28, 2025.
  • -29.6% median (-21.9% mean) 90-day return after 30 previous buys.
  • The trade is 0.0% of the 5,700,030 shares held after it.
  • 3 other insiders bought within 30 days.
  • 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman and CEO KAZIMI A J bought about $45 of CPIX on Aug 29, 2025; 3 other insiders bought within 30 days and 17 funds added in the latest 13F quarter.
Krogulski Kenneth
Director
BUY
2025-09-12 SECtraded 2025-08-29
68
$235
+223.9%
Context
  • 474 earlier Form 4 trades (code P or S) here by this insider (474 buys), the last on Aug 28, 2025.
  • -29.6% median (-21.9% mean) 90-day return after 30 previous buys.
  • The trade is 0.0% of the 289,717 shares held after it.
  • 3 other insiders bought within 30 days.
  • 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Krogulski Kenneth bought about $235 of CPIX on Aug 29, 2025; 3 other insiders bought within 30 days and 17 funds added in the latest 13F quarter.
Young Caroline
Director
BUY
2025-09-12 SECtraded 2025-08-28
6
$21
+223.9%
Context
  • 525 earlier Form 4 trades (code P or S) here by this insider (525 buys), the last on Aug 27, 2025.
  • -28.7% median (-21.0% mean) 90-day return after 30 previous buys.
  • The trade is 0.0% of the 32,936 shares held after it.
  • 3 other insiders bought within 30 days.
  • 17 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Young Caroline bought about $21 of CPIX on Aug 28, 2025; 3 other insiders bought within 30 days and 17 funds added in the latest 13F quarter.
2,234 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 2,229 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
17 funds bought in last quarter
below 71% of Pharma & Biotech
Revenue
+17.6% year over year
more than 65% of Pharma & Biotech
Margin
-6.4% net margin
more than 67% of Pharma & Biotech
Buybacks
$61.0K repurchased, FY to 2026-06-30
below 98% of Pharma & Biotech
Short interest
4.0% of the float short (float per yahoo 2026-10-26) · 7.5 days to cover · settled 2026-09-30
below 64% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch CPIX

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+216.4%12M
-45%+48%+141%+234%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns CPIX: institutional holders (13F)

13F holdings, latest reported quarter
Ikarian Capital, LLC
503,153 sh
$3.3M
RENAISSANCE TECHNOLOGIES LLC
478,263 sh
$3.1M
VANGUARD CAPITAL MANAGEMENT LLC
379,478 sh
$2.5M
DIMENSIONAL FUND ADVISORS LP
233,305 sh
$1.5M
BOOTHBAY FUND MANAGEMENT, LLC
112,544 sh
$729.3K

Congress trades in CPIX

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

CPIX planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

CPIX mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Nationwide Bailard Small Cap Value Fund
$164.5K position · as of 2026-07-31
0.1%
Ultra-Small Company Market Fund
$162.0K position · as of 2026-06-30
0.1%
iShares Micro-Cap ETF
$187.3K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$12.9K position · as of 2026-06-30
0.0%
U.S. MICRO CAP PORTFOLIO
$319.1K position · as of 2026-07-31
0.0%
Small Cap Opportunities Trust
$6.2K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 2 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 1
0 active
4
Phase 2
2 active
2
Phase 4
0 active
What changed recently
Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
2026-09-03 · Completion moved 2027-01 → 2028-01
Phase 2
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$2.2M
$979.8K
$341.2K
+35%
+32%
2024
$1.1M
$979.3K
$315.6K
-54%
-38%
2023
$979.7K
$952.5K
$326.9K
-65%
-57%
2022
$583.4K
$897.5K
$305.6K
-56%
-51%
2021
$1.5M
$872.6K
$411.8K
-9%
-28%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 17 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWSTKYMR

CPIX financials

Revenue growth
+17.6%
XBRL, annual
Net margin
-6.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$39.9M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-27.4%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
$683.9K
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
current debt only, 2025-12-31 (6 months older than the period end); equity 2026-06-30
Cash flow to debt
n/a
no debt to cover
Return on equity
-48.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-16.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$123.3M
market value at close 2026-10-23 on 2026-08-05 shares, plus current debt only, 2025-12-31 (6 months older than the period end), minus cash 2026-06-30
FCF yield
+0.5%
TTM free cash flow over market value at close 2026-10-23
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$44.5M$37.9M$39.6M$42.0M
Operating income-$2.8M-$6.4M-$9.6M-$5.7M
Net income-$2.8M-$6.5M-$6.3M-$5.6M
EPS (diluted)-0.19-0.46-0.44-0.38
Operating cash flow$4.9M-$612.2K$6.1M$8.5M
Cash$11.4M$18.0M$18.3M$19.8M
Buybacks$263.5K$579.0K$740.5K$1.1M
SEC XBRL, fiscal years, as known on 2026-10-27

CPIX Stock Sonar score 5/7 axes

Find similar shapesCompare

CPIX ranks highest on financial health (99th percentile) and risk and compliance (69th), and lowest on institutional and government (29th), among Pharma & Biotech peers.

ProfitHealthGrowthInstitutionsRisk
Profitability
62
Inputs
  • Return on equity-48.1% · 54 pct, sector of 545
  • Return on assets-16.7% · 70 pct, sector of 691
  • Return on invested capitalthe filed year and its quarters do not reconcile, so the trailing figure is withheld
  • Return on capital employedthe filed year and its quarters do not reconcile, so the trailing figure is withheld
Financial health
100
Inputs
  • Debt to equity0.00x · 100 pct, sector of 352
  • Cash flow to debtno debt to cover
Growth
65
Inputs
  • Revenue growth, YoY+17.6% · 65 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Institutional and government
29
Inputs
  • Funds adding, latest quarter17 · 29 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
69
Inputs
  • Short interest, % of float+4.0% · 63 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+6.4% · 75 pct, sector of 511
2 not measured: Insider conviction, US patents
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies